Together with our findings showing that Bortezomib sensitizes neuroblastoma cells towards TRAIL, the currently available data indicate that Bortezomib represents an interesting experimental agent for the treatment of neuroblastoma especially in combination protocols, which warrants further investigation. Here, TNFSF10 is linked to neuroblastoma.